HUTCHMED Data to be Presented at EHA2024 Congress
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your HCM notes
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
Hong Kong, Shanghai & Florham Park, NJ - Friday, May 17, 2024: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM‑01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association ("EHA") Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online.
ESLIM-01 is a randomized, double-blinded, placebo-controlled Phase III trial in China of sovleplenib in adult patients with primary Immune Thrombocytopenia ("ITP") who have received at least one prior line of standard therapy (NCT05029635). In 188 patients randomized to receive oral sovleplenib or placebo, sovleplenib demonstrated a clinically meaningful early and sustained durable platelet response in patients with primary ITP with durable response rate of 48.4% compared to zero with placebo (p<0.0001). The median time to response was 1.1 weeks with sovleplenib. It demonstrated a tolerable safety profile with grade 3 or above treatment-emergent adverse events (TEAEs) in 25.4% of patients with sovleplenib and 24.2% with placebo. Sovleplenib also significantly improved quality of life in physical functioning and energy/fatigue (p<0.05).
Most patients were heavily pretreated with a median of four prior lines of ITP therapy and a majority (71.3%) of the patients had received prior TPO/TPO-RA[1] treatment. Further post-hoc subgroup analysis of the study demonstrated consistent clinical benefits across ITP patients regardless of prior lines of ITP therapies or prior TPO/TPO-RA exposure, regardless of TPO/TPO-RA treatment types and number of prior regimens.
In addition to the promising data in ITP, results from Phase II part of the ongoing ESLIM-02 Phase II/III study (NCT05535933) of sovleplenib for warm antibody autoimmune hemolytic anemia (wAIHA) will also be presented at the congress demonstrating encouraging hemoglobin (Hb) benefit compared with placebo, with overall response rate of 43.8% vs. 0% in the first 8 weeks, and overall response rate of 66.7% during the 24 weeks of sovleplenib treatment (including patients that crossed over from placebo). A favorable safety profile was also demonstrated.
Details of the presentations are as follows:
| Abstract title | Presenter / Lead author | Presentation details |
| Efficacy and Safety of The Syk Inhibitor Sovleplenib (HMPL-523) i n Adult Patients with Primary Immune Thrombocytopenia in China (ESLIM-01): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study | R enchi Yang Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China | #S316 Oral Presentation (Platelet disorders in the spotlight: Clinical and translational) Friday, June 14, 2024 15:00 - 15:15 CEST, Hall Mallo |
| Sovleplenib f or the Treatment of Warm Antibody Autoimmune Hemolytic Anemia ( w AIHA): Results from t he Randomized, Double-Blind, Placebo-Controlled, Phase 2 Part of t he Study | Fengkui Zhang Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China | #S297 Oral Presentation (Thalassemias and rare anemias) Sunday, June 16, 2024 12:00 - 12:15 CEST, Hall Mallo |
| Sovleplenib In Primary Immune Thrombocytopenia (ITP) Patients by Prior Lines of Therapy: Subgroup Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (ESLIM-01) | Xiaofan Liu Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China | #P1629 Poster Session Friday, June 14, 2024 |
| Sovleplenib In Primary Immune Thrombocytopenia (ITP) Pts with Prior TPO/TPO-RA Treatment: Subgroup Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (ESLIM-01) | Heng Mei Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China | #P1631 Poster Session Friday, June 14, 2024 |
| Safety a nd Efficacy o f Syk Inhibitor Sovleplenib i n Heavily P re-Treated Hodgkin Lymphoma Patients | Paolo Strati The University of Texas MD Anderson Cancer Center, Houston, U.S. | #P1102 Poster Session Friday, June 14, 2024 |
| HMPL-306 i n Patients with Relapsed or Refractory Myeloid Hematological Malignancies Harboring I DH 1 and/or IDH2 Mutations: Final Result of Dose Expansion i n Phase 1 Study | Xiaojun Huang Peking University People's Hospital, Beijing, China | #P532 Poster Session Friday, June 14, 2024 |
| Phase 1 Study o f H MPL -306 i n Patients w ith Advanced Acute Myeloid Leukemia w ith Isocitrate Dehydrogenase (I DH ) Mutations: Preliminary Results o f t he Dose Escalation Cohorts | Pau Montesinos Hospital Universitario La Fe, Valencia, Spain | #P549 Poster Session Friday, June 14, 2024 |
| Phase II Study of EZH2 Inhibitor Tazemetostat p lus Amdizalisib, a PI3K Inhibitor, i n Patients with Relapsed/Refractory Lymphomas | Mingci Cai R uijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Chin a | #P2080 e-Poster Presentation Friday, June 14, 2024 |
| Results from a Phase 1 Dose Escalation Study of HMPL-760, a Third Generation, Highly Selective, Reversible BTK Inhibitor in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas | Ying Qian Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Chin a | #P2054 e-Poster Presentation Friday, June 14, 2024 |
| A Phase 1b Study to Evaluate the Safety and Preliminary Efficacy of Sovleplenib, a Syk Inhibitor, in Adult Subjects with Immune Thrombocytopenia | Waleed Ghanima University of Oslo, Oslo, Norway | # PB3341 Publication Only |
Medical Information
[1] TPO = Thrombopoietin; TPO-RAs = Thrombopoietin receptor agonists.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.